AB Science (AB)

Executive Summary

AB Science is a French biotechnology company pioneering small molecule protein kinase inhibitors, with a primary focus on masitinib, a highly selective tyrosine kinase inhibitor, and AB8939, a novel microtubule destabilizer. Masitinib, the company's lead candidate, has been evaluated across a wide range of oncology, neurodegenerative, and inflammatory indications, including advanced mastocytosis, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and COVID-19. Despite mixed clinical outcomes and regulatory setbacks, masitinib has shown signals of efficacy in certain patient subsets, particularly in slow-progressing ALS and severe asthma. AB8939, in earlier development, targets hematologic malignancies with a unique mechanism of action. The company's strategy leverages repurposing opportunities and mechanistic differentiation, though cash runway and commercialization capabilities remain key uncertainties. AB Science is publicly traded in France (Euronext: AB) and has a market capitalization of approximately €3.6 billion, reflecting high investor expectations around upcoming pivotal data.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 results for masitinib in ALS (AB10015 study)40% success
• H1 2027Phase 3 data for masitinib in Alzheimer's disease25% success
• Q4 2026Phase 1/2 data for AB8939 in acute myeloid leukemia30% success